의약품 제조 시장 규모, 점유율, 동향 분석 보고서 : 투여 경로별, 분자 유형별, 의약품 개발 유형별, 판매 채널별, 연령대별, 제형별, 지역별, 부문별 예측(2023-2030년)

Pharmaceutical Manufacturing Market Size, Share & Trends Analysis Report By Route of Administration, By Molecule Type, By Drug Development Type, By Sales Channel, By Age Group, By Formulation, By Region, And Segment Forecasts, 2023 - 2030

US $ 5,950 ￦ 8,163,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,536,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,280,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

의약품 제조 시장 성장 및 동향

Grand View Research의 최신 보고서에 따르면 세계 의약품 제조 시장 규모는 2030년까지 9,299억 달러에 달할 것으로 예상됩니다.

2023년부터 2030년까지 CAGR은 7.63% 성장할 것으로 예상됩니다. 제약 산업은 기술 발전, 비용 효율적인 방법, 투자 증가로 인해 큰 변화를 겪었습니다. 이러한 요인들은 시장 성장에 긍정적인 영향을 미치고 있습니다. 로봇 기술과 인공지능(AI)의 도입은 제조 현장의 다운타임을 줄이고 제품 낭비를 최소화하는 데 중요한 역할을 하고 있습니다. 이러한 기술의 도입은 의약품 제조 공정의 효율성과 생산성을 크게 향상시켰습니다.

또한, 전통적인 오픈 트랜스퍼 제조 방식은 일회용 일회용 솔루션의 채택으로 대체되어 업무 간소화와 오염 위험 감소에 기여하고 있습니다. 또한, 업계에서는 통합적이고 스마트하며 데이터가 풍부한 종이 없는 업무로의 전환이 두드러지게 나타나고 있습니다. 이러한 전환은 오류 없이 정확한 생산 공정을 통해 고품질의 의약품을 생산할 수 있도록 돕고 있습니다. 이러한 시장의 지속적인 발전은 의약품 제조의 발전에 큰 기여를 하고 있습니다. 개인화 의료의 발전은 의료 분야에 혁명을 일으켜 다양한 건강 상태를 대상으로 한 새로운 기회를 제공하고 환자 중심 모델로 가는 길을 열었습니다.

그 결과, 복잡한 의약품과 환자 개개인에 맞는 맞춤형 치료법 개발에 대응하기 위해 대량 생산에서 소량 생산으로의 전환이 진행되고 있습니다. 이러한 변화로 인해 제조업체들은 환자 중심의 의료 시스템에 맞춰 공급망을 재구성해야 하는 상황에 직면해 있습니다. 이러한 모든 요인들이 예측 기간 동안 제약 제조 시장의 성장을 촉진하고 있습니다. 또한, 제약업계의 주요 기업들은 시장 입지를 강화하고 경쟁 우위를 확보하기 위해 전략적 이니셔티브를 취하고 있습니다. 이러한 주요 기업들은 제품 개발, 제휴 및 파트너십 모델, 계약, 사업 확장, M&A 전략 등 다양한 활동에 적극적으로 참여하고 있습니다.

이러한 이니셔티브는 제품 포트폴리오를 강화하고 증가하는 의약품 수요에 대응하기 위한 것입니다. 예를 들어, 페링제약은 2022년 4월 인도 하이데라바드에 통합 제조 및 연구 개발(R&D) 시설을 설립했습니다. 이 시설은 사업 및 역량 확장에 대한 페링의 노력을 강조합니다. 이 시설의 R&D 부서는 포장 개발, 제형 개발, 분석 개발 등의 분야에 초점을 맞추고 있습니다. 페링제약은 이러한 분야에 대한 투자를 통해 제품 공급을 강화하고 진화하는 시장의 요구에 부응하고자 합니다.

의약품 제조 시장 보고서 하이라이트

• 2022년 전통적 의약품(저분자) 분야가 54.9% 이상의 가장 높은 매출 점유율을 차지할 것으로 예상됩니다. 이는 저분자 제품이 쉽게 구할 수 있고 시장 침투율이 높기 때문입니다.
• 2022년 시장 점유율은 아웃소싱 부문이 53% 이상을 차지할 것으로 예상됩니다. 아웃소싱 업무와 관련된 몇 가지 장점은 향후 몇 년 동안 이 분야의 성장을 유리한 속도로 촉진할 것으로 예상됩니다.
• 수익 측면에서는 정제 부문이 2022년 26.08% 이상의 점유율로 시장을 장악했습니다. 이는 필름정, 장용정, 발포정, 구강붕해정 등 다양한 정제 기반 제품 및 유형이 존재하기 때문입니다.
• 경구제 부문은 2022년 58% 이상의 점유율로 세계 시장을 이끌었습니다. 경구용 제형은 가격이 저렴하고 제조가 용이하며 환자 친화적입니다.
• 처방약 부문은 2022년 83.76%의 가장 큰 매출 점유율을 차지할 것이며, 전 세계적으로 처방약 지출이 증가함에 따라 예측 기간 동안 안정적인 CAGR로 더욱 확대될 것으로 보입니다.
• 북미 지역이 2022년 시장을 장악하고 큰 매출 점유율을 차지할 것으로 예상되는 이유는 이 지역에서 특히 오래된 기업과 신생 기업 간의 전략적 제약 제휴가 많이 이루어지고 있기 때문입니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 의약품 제조 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 보급과 성장 전망 매핑
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 의약품 제조 시장 분석 툴
  • 업계 분석 - Porter's
  • PESTEL 분석

제4장 의약품 제조 : 분자 유형 추정·동향 분석

• 정의와 범위
• 시장 점유율, 2022년·2030년
• 부문 대시보드
• 세계 시장 전망
• 시장 규모, 예측 및 동향 분석, 2018-2030년
  • 생물제제 및 바이오시밀러(고분자)
  • 기존 약제(저분자)

제5장 의약품 제조 : 의약품 개발 유형 추정·동향 분석

• 정의와 범위
• 시장 점유율, 2022년·2030년
• 부문 대시보드
• 세계 시장 전망
• 시장 규모, 예측 및 동향 분석, 2018-2030년
  • 사내
  • 아웃소싱

제6장 의약품 제조 : 제형 추정·동향 분석

• 정의와 범위
• 시장 점유율, 2022년·2030년
• 부문 대시보드
• 세계 시장 전망
• 시장 규모, 예측 및 동향 분석, 2018-2030년
  • 정제
  • 캡슐
  • 주사
  • 스프레이
  • 서스펜션
  • 분말
  • 기타

제7장 의약품 제조 : 투여 경로 추정·동향 분석

• 정의와 범위
• 시장 점유율, 2022년·2030년
• 부문 대시보드
• 세계 시장 전망
• 시장 규모, 예측 및 동향 분석, 2018-2030년
  • 경구
  • 외용
  • 비경구
  • 흡입
  • 기타

제8장 의약품 제조 : 치료 분야 추정·동향 분석

• 정의와 범위
• 시장 점유율, 2022년·2030년
• 부문 대시보드
• 세계 시장 전망
• 시장 규모, 예측 및 동향 분석, 2018-2030년
  • 심혈관질환
  • 통증
  • 당뇨병
  • 암
  • 호흡기질환
  • 기타

제9장 의약품 제조 : 처방전 추정·동향 분석

• 정의와 범위
• 시장 점유율, 2022년·2030년
• 부문 대시보드
• 세계 시장 전망
• 시장 규모, 예측 및 동향 분석, 2018-2030년
  • 처방약
  • 시판약(OTC)

제10장 의약품 제조 : 연령층 추정·동향 분석

• 정의와 범위
• 시장 점유율, 2022년·2030년
• 부문 대시보드
• 세계 시장 전망
• 시장 규모, 예측 및 동향 분석, 2018-2030년
  • 아동과 청소년
  • 성인
  • 고령자용

제11장 의약품 제조 : 판매 채널 추정·동향 분석

• 정의와 범위
• 시장 점유율, 2022년·2030년
• 부문 대시보드
• 세계 시장 전망
• 시장 규모, 예측 및 동향 분석, 2018-2030년
  • 소매
  • 비소매

제12장 의약품 제조 시장 : 지역 추정·동향 분석

• 지역 시장 점유율 분석, 2022년 및 2030년
• 지역 시장 대시보드
• 세계의 지역 시장 현황
• 지역 시장 점유율과 주요 기업, 2021년
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• SWOT 분석, 요인별(정치·법률, 경제·기술)
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• 시장 규모, 예측, 수량 및 동향 분석, 2018년에서 2030년 :
• 북미
  • SWOT 분석
  • 북미 시장 추정과 예측, 2018년에서 2030년
  • 미국
  • 캐나다
• 유럽
  • SWOT 분석
  • 유럽 시장 추정과 예측, 2018년에서 2030년
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • SWOT 분석
  • 아시아태평양 시장 추정과 예측, 2018년에서 2030년
  • 중국
  • 일본
  • 인도
  • 호주
  • 태국
  • 한국
• 라틴아메리카
  • SWOT 분석
  • 라틴아메리카 시장 추정과 예측, 2018-2030년
  • 브라질
  • 멕시코
  • 아르헨티나
• 중동 및 아프리카
  • SWOT 분석
  • MEA 시장 추정과 예측, 2018년에서 2030년
  • 사우디아라비아
  • 남아프리카공화국
  • 아랍에미리트
  • 쿠웨이트

제13장 경쟁 상황

• 주요 시장 진출 기업에 의한 최근의 동향과 영향 분석
• 회사/경쟁 분류
  • 이노베이터
• 벤더 상황
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • GlaxoSmithKline plc
  • Pfizer, Inc.
  • Merck &Co., Inc.
  • AstraZeneca
  • Johnson &Johnson Services, Inc.
  • Sanofi SA
  • Eli Lilly and Company
  • AbbVie, Inc.
  • Thermo Fisher Scientific, Inc.
  • Wuxi Apptec
  • Samsung Biologics
  • FUJIFILM Diosynth Biotechnologies USA, Inc.
  • Lonza
  • Catalent Pharma Solutions
  • Jubilant Pharmova Limited

ksm

영문 목차

영문목차

Pharmaceutical Manufacturing Market Growth & Trends

The global pharmaceutical manufacturing market size is expected to reach USD 929.9 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 7.63% from 2023 to 2030. The pharmaceutical industry has undergone significant transformations as a result of technological advancements, cost-effective methods, and increased investments. These factors have had a positive impact on the growth of the market. The implementation of robotic technology and Artificial Intelligence (AI) has played a crucial role in reducing manufacturing floor downtime and minimizing product waste. By incorporating these technologies, efficiency, and productivity in pharmaceutical manufacturing processes have been greatly improved.

In addition, traditional open-transfer manufacturing methods have been replaced by the adoption of single-use disposable solutions, leading to streamlined operations and reduced risks of contamination. Moreover, there has been a notable shift toward integrated, smart, and data-rich paperless operations within the industry. This transition has resulted in error-free and precise production processes, ensuring the production of high-quality pharmaceutical products. These ongoing advancements in the market have significantly contributed to the progress of drug manufacturing. The development of personalized medicine has brought about a revolution in the healthcare sector, offering new opportunities to target various health conditions and paving the way for patient-centric models.

Consequently, there has been a shift from large-scale production to smaller batches to cater to the development of complex medicines and personalized treatments tailored to individual patients. This transformative shift has prompted manufacturers to restructure their supply chains in alignment with the patient-centric healthcare system. All such factors propel pharmaceutical manufacturing market growth over the forecast period. Furthermore, leading companies in the pharmaceutical industry have taken strategic initiatives to enhance their market presence and gain a competitive advantage. These key players actively engage in various activities, such as product development, collaboration & partnership models, agreements, business expansion, and merger & acquisition strategies.

These initiatives are also aimed at strengthening their product portfolios and meeting the growing demand for pharmaceutical products. For instance, in April 2022, Ferring Pharmaceuticals inaugurated an integrated manufacturing and research and development (R&D) facility in Hyderabad, India. This facility underscores Ferring's commitment to expanding its operations and capabilities. The R&D division of the facility focuses on areas, such as packaging development, formulation development, and analytical development. Ferring Pharmaceuticals aims to enhance its product offerings and meet the evolving needs of the market by investing in these areas.

Pharmaceutical Manufacturing Market Report Highlights

• In 2022, the conventional drugs (small molecules) segment accounted for the highest revenue share of over 54.9%. This is attributed to the easy availability of small molecules products, with high market penetration
• The outsourcing segment dominated the market in 2022 with a revenue share of over 53%. Several benefits associated with outsourcing operations are expected to drive the segment growth at a lucrative pace over the coming years
• In terms of revenue, the tablets segment dominated the market with a share of over 26.08 % in 2022. This is due to the wide availability of tablet-based products and types, such as film and enteric-coated, effervescent, and orally disintegrating tablets
• The oral segment led the global market with a share of more than 58% in 2022. Oral dosage forms are affordable, easy to manufacture, and patient-friendly
• The prescription medicines segment accounted for the maximum revenue share of 83.76% in 2022 and will expand further at a steady CAGR over the forecast period due to the growing prescription drug expenditures across the globe
• North America dominated the market and accounted for a significant revenue share in 2022 due to a large number of strategic pharma partnerships, especially among the well-established and early-stage companies, in this region

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Molecule Type
  • 1.2.2. Drug Development Type
  • 1.2.3. Formulation
  • 1.2.4. Routes of Administration
  • 1.2.5. Therapy Area
  • 1.2.6. Prescription
  • 1.2.7. Age Group
  • 1.2.8. Sales Channel
• 1.3. Regional Scope
• 1.4. Estimates and Forecast Timeline
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased database
  • 1.6.2. GVR's internal database
  • 1.6.3. Secondary sources
  • 1.6.4. Primary research
  • 1.6.5. Details of primary research
• 1.7. Information or Data Analysis
  • 1.7.1. Data analysis models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1.1. Commodity flow analysis (Model 1)
  • 1.9.1.2. Approach 1: Commodity flow approach
  • 1.9.1.3. Volume price analysis (Model 2)
  • 1.9.1.4. Approach 2: Volume price analysis
• 1.10. List of Secondary Sources
• 1.11. List of Primary Sources
• 1.12. Objectives
  • 1.12.1. Objective 1
  • 1.12.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Molecule Type outlook
  • 2.2.2. Drug Development Type outlook
  • 2.2.3. Formulation outlook
  • 2.2.4. Route of Administration outlook
  • 2.2.5. Therapy Area outlook
  • 2.2.6. Prescription outlook
  • 2.2.7. Age Group outlook
  • 2.2.8. Sales Channel outlook
  • 2.2.9. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Pharmaceutical Manufacturing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Market Dynamics
  • 3.3.1. Market driver analysis
    • 3.3.1.1. Rise in pharmaceutical R&D spending
    • 3.3.1.2. Rise in focus toward healthcare needs in emerging nations
    • 3.3.1.3. Technological advancements
    • 3.3.1.4. Increase in geriatric population and incidence of chronic disorders
  • 3.3.2. Market restraint analysis
    • 3.3.2.1. Patent expiration of most profitable drugs
    • 3.3.2.2. Pricing pressures on bio/pharmaceutical companies
• 3.4. Pharmaceutical manufacturing Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape

Chapter 4. Pharmaceutical Manufacturing: Molecule Type Estimates & Trend Analysis

• 4.1. Definitions and Scope
  • 4.1.1. Biologics & Biosimilars (Large Molecules)
  • 4.1.2. Conventional Drugs (Small Molecules)
• 4.2. Molecule Type Market Share, 2022 & 2030
• 4.3. Segment Dashboard
• 4.4. Global Pharmaceutical Manufacturing Market by Molecule Type Outlook
• 4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5.1. Biologics & Biosimilars (Large Molecules)
    • 4.5.1.1. Biologics & Biosimilars (Large Molecules) market estimates and forecast 2018 to 2030 (USD Billion)
    • 4.5.1.2. Monoclonal Antibodies
    • 4.5.1.2.1. Monoclonal Antibodies market estimates and forecast 2018 to 2030 (USD Billion)
    • 4.5.1.3. Vaccines
    • 4.5.1.3.1. Vaccines market estimates and forecast 2018 to 2030 (USD Billion)
    • 4.5.1.4. Cell & Gene Therapy
    • 4.5.1.4.1. Cell & Gene Therapy market estimates and forecast 2018 to 2030 (USD Billion)
    • 4.5.1.5. Others
    • 4.5.1.5.1. Others market estimates and forecast 2018 to 2030 (USD Billion)
  • 4.5.2. Conventional Drugs (Small Molecules)
    • 4.5.2.1. Conventional Drugs (Small Molecules) market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 5. Pharmaceutical Manufacturing: Drug Development Type Estimates & Trend Analysis

• 5.1. Definitions and Scope
  • 5.1.1. In-house
  • 5.1.2. Outsource
• 5.2. Drug Development Type Market Share, 2022 & 2030
• 5.3. Segment Dashboard
• 5.4. Global Microneedle Drug Delivery Systems Market by Drug Development Type Outlook
• 5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030for the following
  • 5.5.1. In-house
    • 5.5.1.1. In-house market estimates and forecast 2018 to 2030 (USD Billion)
  • 5.5.2. Outsource
    • 5.5.2.1. Outsource market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 6. Pharmaceutical Manufacturing: Formulation Estimates & Trend Analysis

• 6.1. Definitions and Scope
  • 6.1.1. Tablets
  • 6.1.2. Capsules
  • 6.1.3. Injectable
  • 6.1.4. Sprays
  • 6.1.5. Suspensions
  • 6.1.6. Powders
  • 6.1.7. Others
• 6.2. Formulation Market Share, 2022 & 2030
• 6.3. Segment Dashboard
• 6.4. Global Pharmaceutical Manufacturing Market by Formulation Outlook
• 6.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5.1. Tablets
    • 6.5.1.1. Tablets market estimates and forecast 2018 to 2030 (USD Billion)
  • 6.5.2. Capsules
    • 6.5.2.1. Capsules market estimates and forecast 2018 to 2030 (USD Billion)
  • 6.5.3. Injectable
    • 6.5.3.1. Injectable market estimates and forecast 2018 to 2030 (USD Billion)
  • 6.5.4. Sprays
    • 6.5.4.1. Sprays market estimates and forecast 2018 to 2030 (USD Billion)
  • 6.5.5. Suspensions
    • 6.5.5.1. Suspensions market estimates and forecast 2018 to 2030 (USD Billion)
  • 6.5.6. Powders
    • 6.5.6.1. Powders market estimates and forecast 2018 to 2030 (USD Billion)
  • 6.5.7. Others
    • 6.5.7.1. Others market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 7. Pharmaceutical Manufacturing: Route of Administration Estimates & Trend Analysis

• 7.1. Definitions and Scope
  • 7.1.1. Oral
  • 7.1.2. Topical
  • 7.1.3. Parenteral
  • 7.1.4. Inhalations
  • 7.1.5. Others
• 7.2. Route of Administration Market Share, 2022 & 2030
• 7.3. Segment Dashboard
• 7.4. Global Pharmaceutical Manufacturing Market by Route of Administration Outlook
• 7.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.5.1. Oral
    • 7.5.1.1. Oral market estimates and forecast 2018 to 2030 (USD Billion)
  • 7.5.2. Topical
    • 7.5.2.1. Topical market estimates and forecast 2018 to 2030 (USD Billion)
  • 7.5.3. Parenteral
    • 7.5.3.1. Parenteral market estimates and forecast 2018 to 2030 (USD Billion)
  • 7.5.4. Inhalations
    • 7.5.4.1. Inhalations market estimates and forecast 2018 to 2030 (USD Billion)
  • 7.5.5. Others
    • 7.5.5.1. Others market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 8. Pharmaceutical Manufacturing: Therapy Area Estimates & Trend Analysis

• 8.1. Definitions and Scope
  • 8.1.1. Cardiovascular diseases
  • 8.1.2. Pain
  • 8.1.3. Diabetes
  • 8.1.4. Cancer
  • 8.1.5. Respiratory diseases
  • 8.1.6. Others
• 8.2. Therapy Area Market Share, 2022 & 2030
• 8.3. Segment Dashboard
• 8.4. Global Pharmaceutical Manufacturing Market by Therapy Area Outlook
• 8.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.5.1. Cardiovascular diseases
    • 8.5.1.1. Cardiovascular diseases market estimates and forecast 2018 to 2030 (USD Billion)
  • 8.5.2. Pain
    • 8.5.2.1. Pain market estimates and forecast 2018 to 2030 (USD Billion)
  • 8.5.3. Diabetes
    • 8.5.3.1. Diabetes market estimates and forecast 2018 to 2030 (USD Billion)
  • 8.5.4. Cancer
    • 8.5.4.1. Cancer market estimates and forecast 2018 to 2030 (USD Billion)
  • 8.5.5. Respiratory diseases
    • 8.5.5.1. Respiratory diseases market estimates and forecast 2018 to 2030 (USD Billion)
  • 8.5.6. Others
    • 8.5.6.1. Others market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 9. Pharmaceutical Manufacturing: Prescription Estimates & Trend Analysis

• 9.1. Definitions and Scope
  • 9.1.1. Prescription Medicines
  • 9.1.2. Over-the-counter (OTC) medicines
• 9.2. Prescription Market Share, 2022 & 2030
• 9.3. Segment Dashboard
• 9.4. Global Pharmaceutical Manufacturing Market by Prescription Outlook
• 9.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 9.5.1. Prescription Medicines
    • 9.5.1.1. Prescription Medicines market estimates and forecast 2018 to 2030 (USD Billion)
  • 9.5.2. Over-the-counter (OTC) medicines
    • 9.5.2.1. Over-the-counter (OTC) medicines market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 10. Pharmaceutical Manufacturing: Age Group Estimates & Trend Analysis

• 10.1. Definitions and Scope
  • 10.1.1. Children & Adolescents
  • 10.1.2. Adults
  • 10.1.3. Geriatric
• 10.2. Age Group Market Share, 2022 & 2030
• 10.3. Segment Dashboard
• 10.4. Global Pharmaceutical Manufacturing Market by Age Group Outlook
• 10.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030for the following
  • 10.5.1. Children & Adolescents
    • 10.5.1.1. Children & Adolescents market estimates and forecast 2018 to 2030 (USD Billion)
  • 10.5.2. Adults
    • 10.5.2.1. Adults market estimates and forecast 2018 to 2030 (USD Billion)
  • 10.5.3. Geriatric
    • 10.5.3.1. Geriatric market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 11. Pharmaceutical Manufacturing: Sales Channel Estimates & Trend Analysis

• 11.1. Definitions and Scope
  • 11.1.1. Retail
  • 11.1.2. Non-retail
• 11.2. Sales Channel Market Share, 2022 & 2030
• 11.3. Segment Dashboard
• 11.4. Global Pharmaceutical Manufacturing Market by Sales Channel Outlook
• 11.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 11.5.1. Retail
    • 11.5.1.1. Retail market estimates and forecast 2018 to 2030 (USD Billion)
  • 11.5.2. Non-retail
    • 11.5.2.1. Non-retail market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 12. Pharmaceutical Manufacturing Market: Regional Estimates & Trend Analysis

• 12.1. Regional market share analysis, 2022 & 2030
• 12.2. Regional Market Dashboard
• 12.3. Global Regional Market Snapshot
• 12.4. Regional Market Share and Leading Players, 2021
  • 12.4.1. North America
  • 12.4.2. Europe
  • 12.4.3. Asia Pacific
  • 12.4.4. Latin America
  • 12.4.5. Middle East and Africa
• 12.5. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
  • 12.5.1. North America
  • 12.5.2. Europe
  • 12.5.3. Asia Pacific
  • 12.5.4. Latin America
  • 12.5.5. Middle East and Africa
• 12.6. Market Size, & Forecasts, Volume and Trend Analysis, 2018 to 2030:
• 12.7. North America
  • 12.7.1. SWOT Analysis
  • 12.7.2. North America Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 12.7.3. U.S.
    • 12.7.3.1. Key Country Dynamics
    • 12.7.3.2. Target Disease Prevalence
    • 12.7.3.3. Competitive Scenario
    • 12.7.3.4. Regulatory Framework
    • 12.7.3.5. U.S. Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 12.7.4. Canada
    • 12.7.4.1. Key Country Dynamics
    • 12.7.4.2. Target Disease Prevalence
    • 12.7.4.3. Competitive Scenario
    • 12.7.4.4. Regulatory Framework
    • 12.7.4.5. Canada Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
• 12.8. Europe
  • 12.8.1. SWOT Analysis
  • 12.8.2. Europe Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 12.8.3. UK
    • 12.8.3.1. Key Country Dynamics
    • 12.8.3.2. Target Disease Prevalence
    • 12.8.3.3. Competitive Scenario
    • 12.8.3.4. Regulatory Framework
    • 12.8.3.5. UK Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 12.8.4. Germany
    • 12.8.4.1. Key Country Dynamics
    • 12.8.4.2. Target Disease Prevalence
    • 12.8.4.3. Competitive Scenario
    • 12.8.4.4. Regulatory Framework
    • 12.8.4.5. Germany Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 12.8.5. France
    • 12.8.5.1. Key Country Dynamics
    • 12.8.5.2. Target Disease Prevalence
    • 12.8.5.3. Competitive Scenario
    • 12.8.5.4. Regulatory Framework
    • 12.8.5.5. France Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 12.8.6. Italy
    • 12.8.6.1. Key Country Dynamics
    • 12.8.6.2. Target Disease Prevalence
    • 12.8.6.3. Competitive Scenario
    • 12.8.6.4. Regulatory Framework
    • 12.8.6.5. Italy Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 12.8.7. Spain
    • 12.8.7.1. Key Country Dynamics
    • 12.8.7.2. Target Disease Prevalence
    • 12.8.7.3. Competitive Scenario
    • 12.8.7.4. Regulatory Framework
    • 12.8.7.5. Spain Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 12.8.8. Denmark
    • 12.8.8.1. Key Country Dynamics
    • 12.8.8.2. Target Disease Prevalence
    • 12.8.8.3. Competitive Scenario
    • 12.8.8.4. Regulatory Framework
    • 12.8.8.5. Denmark Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 12.8.9. Sweden
    • 12.8.9.1. Key Country Dynamics
    • 12.8.9.2. Target Disease Prevalence
    • 12.8.9.3. Competitive Scenario
    • 12.8.9.4. Regulatory Framework
    • 12.8.9.5. Sweden Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 12.8.10. Norway
    • 12.8.10.1. Key Country Dynamics
    • 12.8.10.2. Target Disease Prevalence
    • 12.8.10.3. Competitive Scenario
    • 12.8.10.4. Regulatory Framework
    • 12.8.10.5. Norway Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
• 12.9. Asia Pacific
  • 12.9.1. SWOT Analysis
  • 12.9.2. Asia Pacific Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 12.9.3. China
    • 12.9.3.1. Key Country Dynamics
    • 12.9.3.2. Target Disease Prevalence
    • 12.9.3.3. Competitive Scenario
    • 12.9.3.4. Regulatory Framework
    • 12.9.3.5. China Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 12.9.4. Japan
    • 12.9.4.1. Key Country Dynamics
    • 12.9.4.2. Target Disease Prevalence
    • 12.9.4.3. Competitive Scenario
    • 12.9.4.4. Regulatory Framework
    • 12.9.4.5. Japan Market estimates and forecast, 2018 - 2030 (Volume, Thousand)
  • 12.9.5. India
    • 12.9.5.1. Key Country Dynamics
    • 12.9.5.2. Target Disease Prevalence
    • 12.9.5.3. Competitive Scenario
    • 12.9.5.4. Regulatory Framework
    • 12.9.5.5. India Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 12.9.6. Australia
    • 12.9.6.1. Key Country Dynamics
    • 12.9.6.2. Target Disease Prevalence
    • 12.9.6.3. Competitive Scenario
    • 12.9.6.4. Regulatory Framework
    • 12.9.6.5. Australia Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 12.9.7. Thailand
    • 12.9.7.1. Key Country Dynamics
    • 12.9.7.2. Target Disease Prevalence
    • 12.9.7.3. Competitive Scenario
    • 12.9.7.4. Regulatory Framework
    • 12.9.7.5. Thailand Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 12.9.8. South Korea
    • 12.9.8.1. Key Country Dynamics
    • 12.9.8.2. Target Disease Prevalence
    • 12.9.8.3. Competitive Scenario
    • 12.9.8.4. Regulatory Framework
    • 12.9.8.5. South Korea Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
• 12.10. Latin America
  • 12.10.1. SWOT Analysis
  • 12.10.2. Latin America Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 12.10.3. Brazil
    • 12.10.3.1. Key Country Dynamics
    • 12.10.3.2. Target Disease Prevalence
    • 12.10.3.3. Competitive Scenario
    • 12.10.3.4. Regulatory Framework
    • 12.10.3.5. Brazil Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 12.10.4. Mexico
    • 12.10.4.1. Key Country Dynamics
    • 12.10.4.2. Target Disease Prevalence
    • 12.10.4.3. Competitive Scenario
    • 12.10.4.4. Regulatory Framework
    • 12.10.4.5. Mexico Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 12.10.5. Argentina
    • 12.10.5.1. Key Country Dynamics
    • 12.10.5.2. Target Disease Prevalence
    • 12.10.5.3. Competitive Scenario
    • 12.10.5.4. Regulatory Framework
    • 12.10.5.5. Argentina Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
• 12.11. MEA
  • 12.11.1. SWOT Analysis
  • 12.11.2. MEA Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 12.11.3. Saudi Arabia
    • 12.11.3.1. Key Country Dynamics
    • 12.11.3.2. Target Disease Prevalence
    • 12.11.3.3. Competitive Scenario
    • 12.11.3.4. Regulatory Framework
    • 12.11.3.5. Saudi Arabia Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 12.11.4. South Africa
    • 12.11.4.1. Key Country Dynamics
    • 12.11.4.2. Target Disease Prevalence
    • 12.11.4.3. Competitive Scenario
    • 12.11.4.4. Regulatory Framework
    • 12.11.4.5. South Africa Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 12.11.5. UAE
    • 12.11.5.1. Key Country Dynamics
    • 12.11.5.2. Target Disease Prevalence
    • 12.11.5.3. Competitive Scenario
    • 12.11.5.4. Regulatory Framework
    • 12.11.5.5. UAE Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 12.11.6. Kuwait
    • 12.11.6.1. Key Country Dynamics
    • 12.11.6.2. Target Disease Prevalence
    • 12.11.6.3. Competitive Scenario
    • 12.11.6.4. Regulatory Framework
    • 12.11.6.5. Kuwait Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)

Chapter 13. Competitive Landscape

• 13.1. Recent Developments & Impact Analysis, By Key Market Participants
• 13.2. Company/Competition Categorization
  • 13.2.1. Innovators
• 13.3. Vendor Landscape
  • 13.3.1. List of key distributors and channel partners
  • 13.3.2. Key customers
  • 13.3.3. Key company market share analysis, 2022
  • 13.3.4. F. Hoffmann-La Roche Ltd.
    • 13.3.4.1. Company overview
    • 13.3.4.2. Financial performance
    • 13.3.4.3. Product benchmarking
    • 13.3.4.4. Strategic initiatives
  • 13.3.5. Novartis AG
    • 13.3.5.1. Company overview
    • 13.3.5.2. Financial performance
    • 13.3.5.3. Product benchmarking
    • 13.3.5.4. Strategic initiatives
  • 13.3.6. GlaxoSmithKline plc
    • 13.3.6.1. Company overview
    • 13.3.6.2. Financial performance
    • 13.3.6.3. Product benchmarking
    • 13.3.6.4. Strategic initiatives
  • 13.3.7. Pfizer, Inc.
    • 13.3.7.1. Company overview
    • 13.3.7.2. Financial performance
    • 13.3.7.3. Product benchmarking
    • 13.3.7.4. Strategic initiatives
  • 13.3.8. Merck & Co., Inc.
    • 13.3.8.1. Company overview
    • 13.3.8.2. Financial performance
    • 13.3.8.3. Product benchmarking
    • 13.3.8.4. Strategic initiatives
  • 13.3.9. AstraZeneca
    • 13.3.9.1. Company overview
    • 13.3.9.2. Financial performance
    • 13.3.9.3. Product benchmarking
    • 13.3.9.4. Strategic initiatives
  • 13.3.10. Johnson & Johnson Services, Inc.
    • 13.3.10.1. Company overview
    • 13.3.10.2. Financial performance
    • 13.3.10.3. Product benchmarking
    • 13.3.10.4. Strategic initiatives
  • 13.3.11. Sanofi SA
    • 13.3.11.1. Company overview
    • 13.3.11.2. Financial performance
    • 13.3.11.3. Product benchmarking
    • 13.3.11.4. Strategic initiatives
  • 13.3.12. Eli Lilly and Company
    • 13.3.12.1. Company overview
    • 13.3.12.2. Financial performance
    • 13.3.12.3. Product benchmarking
    • 13.3.12.4. Strategic initiatives
  • 13.3.13. AbbVie, Inc.
    • 13.3.13.1. Company overview
    • 13.3.13.2. Financial performance
    • 13.3.13.3. Product benchmarking
    • 13.3.13.4. Strategic initiatives
  • 13.3.14. Thermo Fisher Scientific, Inc.
    • 13.3.14.1. Company overview
    • 13.3.14.2. Financial performance
    • 13.3.14.3. Product benchmarking
    • 13.3.14.4. Strategic initiatives
  • 13.3.15. Wuxi Apptec
    • 13.3.15.1. Company overview
    • 13.3.15.2. Financial performance
    • 13.3.15.3. Product benchmarking
    • 13.3.15.4. Strategic initiatives
  • 13.3.16. Samsung Biologics
    • 13.3.16.1. Company overview
    • 13.3.16.2. Financial performance
    • 13.3.16.3. Product benchmarking
    • 13.3.16.4. Strategic initiatives
  • 13.3.17. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
    • 13.3.17.1. Company overview
    • 13.3.17.2. Financial performance
    • 13.3.17.3. Product benchmarking
    • 13.3.17.4. Strategic initiatives
  • 13.3.18. Lonza
    • 13.3.18.1. Company overview
    • 13.3.18.2. Financial performance
    • 13.3.18.3. Product benchmarking
    • 13.3.18.4. Strategic initiatives
  • 13.3.19. Catalent Pharma Solutions
    • 13.3.19.1. Company overview
    • 13.3.19.2. Financial performance
    • 13.3.19.3. Product benchmarking
    • 13.3.19.4. Strategic initiatives
  • 13.3.20. Jubilant Pharmova Limited
    • 13.3.20.1. Company overview
    • 13.3.20.2. Financial performance
    • 13.3.20.3. Product benchmarking
    • 13.3.20.4. Strategic initiatives

관련자료